UNSPSC 85215402: Diagnosis of intermediate lesions of pinta

This classification denotes the group of activities that yields a diagnosis of Intermediate lesions of pinta. Intermediate lesions of pinta is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as a four digit category under code A67. 1

UNSPSC 85215402 Diagnosis of intermediate lesions of pinta is a Commodity code that shows minimal alignment with recent state and local procurement activity. The three most recent opportunities tagged under this code cover diagnostic imaging PACS (Picture Archiving and Communication System) implementation, special education contracted services, and temporary health professional staffing — none of which involve diagnosis of pinta or related dermatological conditions. The code nominally describes a narrow clinical diagnostic service; the recent solicitations span health IT infrastructure, education staffing, and temporary clinical personnel placement across multiple specialties. This divergence suggests either miscoding in the underlying solicitations or that the code is not actively used by state and local health systems for its intended purpose.

The three recent opportunities originate from health system and school district buyers in California (San Mateo County and Santa Clara County) and Texas (Birdville Independent School District), with response dates clustering between October 7 and October 21, 2026. San Mateo Medical Center's PACS RFP (due October 21, 2026) involves enterprise imaging infrastructure supporting approximately 65,000 radiology studies annually; Santa Clara Health System's RFQ (due October 7, 2026) targets temporary staffing across 13 ancillary clinical categories on a non-exclusive, multiple-award basis; Birdville ISD's sealed proposal (due October 21, 2026) covers 23 line items of special education services with an estimated cost of $398,494.30. None of these solicitations directly procure diagnostic services for pinta or intermediate lesion analysis. The code warrants careful review before pursuit; recent activity does not support a meaningful market signal under this code's stated scope.